Ivan Kairatov is a leading biopharma expert with a deep understanding of how generative artificial intelligence is reshaping the landscape of drug development. With extensive experience in research and development, he has been at the forefront of integrating computational biology with traditional pharmacological methods. In this conversation, we explore the complexities of gynecological health and the potential of AI to solve long-standing challenges in women’s medicine, specifically through the lens of recent advancements in target identification.
Endometriosis affects roughly 190 million women globally and often presents alongside uterine fibroids or adenomyosis. How do these co-occurring conditions complicate the diagnostic process, and what specific biological markers are most critical when trying to differentiate between these various gynecological disorders?
The primary complication lies in the significant biological overlap between these conditions, which often share symptoms like chronic pain and infertility, leading to years of diagnostic delay for millions of women. When endometriosis, which impacts 190 million patients, co-exists with adenomyosis or fibroids, the clinical picture becomes incredibly “noisy,” making it difficult to pinpoint which pathology is driving the patient’s distress. To untangle this, we look for highly specific biological markers that indicate context-dependent activity, such as unique protein expressions or genetic signatures that are exclusive to one condition. By leveraging AI engines like PandaOmics, we can sift through this complexity to identify the most critical targets that differentiate a simple fibroid from invasive endometriotic tissue. This approach moves us away from generalized treatments toward precision medicine that addresses the specific molecular drivers of each patient’s unique combination of disorders.
Using multi-modal data to identify context-dependent patterns can help predict which therapeutic targets will actually succeed in clinical stages. What are the primary technical hurdles when integrating diverse data types into disease-specific models, and how do you ensure these models prioritize novel candidates over established ones?
The most significant technical hurdle is the “integration of siloes,” where transcriptomic, proteomic, and clinical data formats don’t naturally speak the same language. We overcome this by using advanced frameworks like TargetPro, which are designed to harmonize these multi-modal inputs into a unified disease-specific model that can recognize patterns humans might miss. To ensure we aren’t just rediscovering well-known targets, the AI is programmed to weigh the “novelty” and “druggability” of a candidate against its historical presence in scientific literature. This allows the system to bypass established clinical targets and instead nominate high-potential, novel candidates that are optimized for immediate preclinical validation. It is a rigorous filtering process that ensures our research resources are funneled into truly innovative breakthroughs rather than incremental improvements.
Moving from AI-generated disease hypotheses to physical validation requires a seamless handoff between computational teams and laboratory researchers. What does the step-by-step workflow look like when transitioning a predicted target into the validation phase, and what metrics determine if a target is ready for preclinical development?
The workflow begins with the AI identifying a disease hypothesis, which is then scrutinized by the Target Discovery team to ensure biological plausibility before any “wet lab” work starts. Once a target is nominated, the transition involves a handoff to specialized laboratory teams who conduct series of in vitro and in vivo experiments to see if the AI’s predictions hold up in living systems. We measure success through specific metrics such as translational potential, which assesses how well the bench-top results might reflect human clinical outcomes. A target is only deemed ready for full preclinical development when it demonstrates a high degree of confidence in its ability to modulate the disease pathway without causing prohibitive toxicity. This collaborative loop between computational insights and physical evidence is what allows us to accelerate the timeline from a computer screen to a potential life-changing therapy.
Specialized expertise in obstetrics and gynecology is essential for addressing long-standing unmet medical needs in women’s health. How does focusing on a specific therapeutic niche change the approach to drug discovery, and what are the practical trade-offs when balancing speed with the need for high-quality clinical outcomes?
Focusing on a niche like gynecology changes the approach by allowing us to dive much deeper into the hormonal and reproductive complexities that are often overlooked in broader internal medicine studies. By partnering with companies that have deep-rooted expertise in this field, we can apply AI to very specific biological landscapes, ensuring the “roadmap” we create is accurate for conditions like adenomyosis. The trade-off between speed and quality is managed by using AI to fail fast; we can discard thousands of unpromising leads in seconds, which actually preserves the quality of the final candidates. This increased efficiency means we don’t have to sacrifice rigor for the sake of speed, ultimately leading to better clinical outcomes for the hundreds of millions of women who have been waiting for new treatment options. It turns the traditional trial-and-error method into a targeted strike against the disease.
What is your forecast for AI-driven gynecological drug discovery?
I believe we are entering an era where the diagnostic and treatment gap in women’s health will finally begin to close as AI moves from a supportive tool to the primary engine of discovery. In the coming years, the integration of generative AI across all stages of R&D will likely lead to the rapid identification of high-quality drug targets that were previously hidden in complex data. We will see a shift toward personalized gynecological care where treatments are tailored to the specific molecular profile of a patient’s endometriosis or fibroids. Ultimately, this technology will transform these chronic, debilitating conditions into manageable or even curable diseases, significantly reducing the global disease burden and improving reproductive health for future generations.
